Agilent Technologies Named Company of the Year by Instrument Business Outlook
News Jan 27, 2011
Agilent Technologies, Inc. has been named 2010 Company of the Year by Instrument Business Outlook. The newsletter, published by analyst firm Strategic Directions International, Inc., covers the scientific instrument industry.
Agilent was singled out in the Jan. 15 issue based on “financial performance, market leadership, product introductions and key strategic investments.”
“2010 was a significant year for Agilent as we kept customer satisfaction a top priority while driving the Varian integration,” said Mike McMullen, president, Agilent Chemical Analysis Group. “The acquisition expanded our product portfolio with strategic additions like atomic spectroscopy systems and vacuum technologies. It was one more example of how we’ve been steadfastly committed to our vision through the economic downturn and are emerging stronger than ever as the economy recovers. IBO’s recognition of these achievements is a rewarding finish to a banner year.”
The publication pointed out that Agilent’s Chemical Analysis Group had 2010 revenue growth of 73 percent over the previous year “mostly because of Agilent’s acquisition of Varian” and cited organic growth up “a remarkable 17 percent.” The article also noted that the company’s Life Sciences Group had revenue growth of 35 percent over fiscal 2009, including the Varian acquisition, and organic growth of 17 percent. In Agilent’s third business, the Electronic Measurement Group, revenue grew 24 percent.
“It’s great to achieve this distinction from this credible industry observer,” said Nick Roelofs, Ph.D., president, Agilent Life Sciences Group. “Agilent is laser-focused on retaining customer trust, increasing market reach, expanding the scale and scope of our offerings and investing in technology leadership. This has enabled us to gain market share faster than many of our competitors and consistently achieve the industry’s highest customer-satisfaction ratings.”
Notable product introductions cited in the article include GC/MS, ICP-MSand GC triple quadrupole MS systems, to increase Agilent’s leadership in GC and GC/MS.
In life sciences, the article said, “particularly strong results were evident in academic and government markets, as well as for pharma and biotech, much of which is attributable to success with the new LCand LC/MSproducts and the genomics product lines.”
“But what really made Agilent special in 2010 was its acquisition of Varian,” the article continued. “Although most companies take a year or more to fully integrate major acquisitions, Agilent did it in six months. Profits were up for existing Agilent products as well as for Varian products, which was an achievement given the uncertainties of such a long period between announcement and closure.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019